Compounded Semaglutide: Does It Work, Is It Safe, and Is It Still Legal?

Compounding is when a pharmacist or physician prepares a medicine for a patient whose needs an approved drug cannot meet, for example by leaving out an ingredient the patient is allergic to.1 Compounded semaglutide is usually sold as an injectable solution in a vial, prepared by a pharmacy instead of by Novo Nordisk, which makes Ozempic, Wegovy and Rybelsus.

The FDA's position on all compounded drugs applies here: they are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are sold.1

There are two kinds of compounder. 503A pharmacies are state-licensed and overseen mainly by state boards of pharmacy; 503B outsourcing facilities register with the FDA, are inspected on a risk-based schedule and must meet manufacturing-quality (CGMP) rules.1 Our outsourcing facilities page explains the difference in more detail.

Approved semaglutide has been tested in large trials and reviewed by the FDA; compounded semaglutide has not.1

• Evidence. Wegovy's 2.4 mg dose produced an average weight change of −14.9% at 68 weeks in the STEP 1 trial, against −2.4% with placebo.9 That evidence applies to the approved product; compounded products have not been through FDA review.1
• Ingredient. The FDA says some compounded semaglutide may use salt forms that differ from the active ingredient in the approved drugs (see below).3
• Form. Wegovy comes as prefilled pens and as a once-daily tablet at set strengths.10 Compounded products often come in multi-dose vials that require the user to draw up each dose.3
• Marketing claims. The FDA says compounded products may not be promoted as generic versions of approved drugs, as using "the same active ingredient," or as clinically proven.5

For a side-by-side look, see compounded semaglutide vs Ozempic, and our explainer on what Ozempic is.

There are no FDA-reviewed trials of compounded semaglutide products, so there is no approved evidence of how well any given product works.1 The trial results people quote, such as STEP 1, were produced with the approved drug.9 The FDA has said telehealth companies may not describe compounded GLP-1s as "clinically proven to produce results."5

Whether a specific compounded product performs like the approved drug depends on what is actually in the vial, its strength, sterility and how it is stored and dosed — the things the FDA does not check in advance for compounded drugs.1,3

The FDA has documented several specific risks.

• Adverse event reports. As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide. It notes that state-licensed pharmacies that are not outsourcing facilities are not required to report, so the figure is likely an undercount.3
• Dosing errors. The FDA has received multiple reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide — including patients measuring the wrong amount and clinicians miscalculating doses.3
• Storage. The FDA advises discarding multi-dose compounded vials 28 days after first use, and not using an injectable GLP-1 that arrives warm.3
• Ingredient sourcing. Since September 2025, an FDA import alert lets semaglutide and tirzepatide ingredients from facilities the FDA has not verified be detained at the border.8
• Counterfeits and research products. The FDA warns about counterfeit Ozempic and about products labeled "for research purposes" or "not for human consumption" that are sold for people to inject.3

The approved drugs carry their own warnings too, including a boxed warning about thyroid C-cell tumors seen in rodents.10 More on how to spot unsafe sellers is on our safety hub.

The FDA has warned that some compounded products may use semaglutide sodium or semaglutide acetate, which are different active ingredients from the one in the approved drugs.3

The agency says it has no information on whether these salt forms are equivalent to the approved ingredient, and that it is not aware of any lawful basis for compounding with them.3 When comparing products, asking the pharmacy which form of semaglutide it uses is a reasonable question.

Only under narrow conditions now that the shortage has ended. The timeline, as the FDA published it:2

• February 21, 2025: the FDA determined the semaglutide shortage was resolved, giving 503A pharmacies until April 22, 2025 and 503B facilities until May 22, 2025.
• April 28, 2025: after a court denied a preliminary injunction, the 503A grace period ended, and the 503B period ran to May 22, 2025.
• April 1, 2026: the FDA restated the rules and confirmed that semaglutide is on neither the drug shortage list nor the 503B bulks list.

Under the rules described in that update, a 503A pharmacy may compound semaglutide for an individual patient on a prescription, but may not regularly or in inordinate amounts make drugs that are "essentially a copy" of an approved product.2 A copy means the same active ingredient in the same, similar or easily substitutable strength, by the same route — unless a prescriber documents that the change makes a significant difference for that patient.2

The FDA gave a pointed example: adding vitamin B12 does not by itself make a product different. A semaglutide-plus-B12 product can still be essentially a copy when both amounts are within 10% of the strengths of commercially available products.2 The agency has also said it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a month.2

503B outsourcing facilities may not compound semaglutide from bulk ingredients while it is off both lists, and on April 30, 2026 the FDA proposed to formally exclude it from the 503B bulks list; comments closed on June 29, 2026.2,4 Our status tracker follows what happens next.

The FDA has stepped up enforcement against how compounded GLP-1s are marketed online. On February 6, 2026 it said it would act against companies mass-marketing compounded GLP-1s with misleading claims, and warned that failure to correct violations could lead to seizure or injunction.5 On March 3, 2026 it announced warning letters to 30 telehealth companies over claims implying sameness with approved drugs and branding that hid who compounded the product.6

Its June 2026 guidance lists the practices it considers misleading, including calling a compounded drug "FDA-approved" or a "generic," and describing a pharmacy as "FDA-approved" or "FDA-licensed."7 We track these letters on our warning letters page.

Every legitimate route starts with a prescription from a licensed clinician and a state-licensed pharmacy. That is the FDA's own advice, along with its BeSafeRx resources for buying medicines online safely.3

The approved options are:

• Wegovy injection, sold by NovoCare Pharmacy for $349 a month for 0.25 mg to 2.4 mg, with an introductory $199 for the first two fills of 0.25 mg and 0.5 mg through December 31, 2026.12
• Wegovy tablets, $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg via NovoCare Pharmacy.12
• Ozempic, approved for type 2 diabetes and usually covered under that indication.11

If you are considering compounded semaglutide online, the FDA's guidance suggests checking who actually compounds it, whether it is presented as approved or generic, and which form of semaglutide it contains.3,7 Our compounded semaglutide ranking and semaglutide online guide set out current options and verified prices.

Is compounded semaglutide the same as Ozempic or Wegovy? No. It is not FDA-approved, may use a different salt form, and the FDA treats "same as" or "generic" claims for compounded drugs as misleading.1,3,7

Is compounded semaglutide safe? The FDA does not verify its safety before sale and had received 990 adverse event reports for compounded semaglutide as of May 31, 2026, including reports linked to dosing errors.1,3

What are semaglutide salts? Semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and the FDA says it is not aware of a lawful basis for compounding with them.3

When did the semaglutide shortage end? The FDA declared it resolved on February 21, 2025.2

Can I still get compounded semaglutide with B12? Adding B12 does not on its own stop a product from being a copy of an approved drug; it depends on the strengths and on a documented clinical need.2

To compare providers that still offer compounded semaglutide and disclose their pharmacy, see our ranking of the best compounded semaglutide providers. If you are open to brand-name options, our guide to tirzepatide vs semaglutide and compounded tirzepatide cover the alternatives.

This article is for information only and is not medical or legal advice. Compounded drugs are not FDA-approved. Talk to a licensed clinician before starting or switching any GLP-1 treatment.